A Phase 1/2 interventional study of ALN-2232 and Placebo in Obesity, sponsored by Alnylam Pharmaceuticals. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Alnylam Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 574 studies in Obesity with a site in Canada — 101 open to participants now, 150 under way, 46 of them phase 3. Obesity · Canada.
Among the 574 studies in Obesity with a site in Canada, this one is the 159th largest by planned enrollment of the 479 interventional ones that give a count, is one of 53 that started in 2026, is one of 10 in phase 1/2, reaches primary completion later than 67 of the 149 other live ones, and was the 541st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →101 of the 574 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–80
Pfizer · Sites in Canada, United States
Ages 18+
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Amgen · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
574 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 63 · Phase 3 97 · Phase 4 26
First in 1997; this study’s year is marked. 53 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 73 across the 479 interventional studies, 52 across the 91 observational. Of the 362 that completed or were terminated, 49 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
162 of 574 have an industry lead sponsor. The 10 most frequent:
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
Alnylam Pharmaceuticals has 4 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
46 of the studies in Obesity with a site in Canada that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 46 to your calendar (.ics) → With an account.
Among the 574 studies in Obesity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Parts:
Exclusion Criteria:
All Parts:
Note: other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered a single dose of ALN-2232
Drug: ALN-2232
Participants will be administered a single dose of placebo
Drug: Placebo
Participants will be administered multiple doses of ALN-2232
Drug: ALN-2232
Participants will be administered multiple doses of placebo
Drug: Placebo
Participants will be administered multiple doses of ALN-2232
Drug: ALN-2232 · Drug: Tirzepatide
Participants will be administered multiple doses of placebo
Drug: Placebo
Participants will be administered multiple doses of tirzepatide once weekly
Drug: Tirzepatide
ALN-2232 will be administered subcutaneously (SC)
Placebo will be administered SC
Tirzepatide will be administered SC
Part A: Frequency of Adverse Events (AEs)
Time frame: Up to 12 months
Part B: Percent Change from Baseline in Body Weight
Time frame: Baseline up to Month 6
Part C: Percent Change from Baseline in Body Weight
Time frame: Baseline up to Month 6
Part A: Change from Baseline in Proteins in Adipose Tissue
Time frame: Baseline up to Month 12
Part A: Area Under the Plasma Concentration-time Curve (AUC) of ALN-2232 in Plasma
Time frame: Predose and up to 15 days postdose
Part A: Maximum Observed Plasma Concentration (Cmax) of ALN-2232 in Plasma
Time frame: Predose and up to 15 days postdose
Part A: Time to Maximum Plasma Concentration (Tmax) of ALN-2232 in Plasma
Time frame: Predose and up to 15 days postdose
Part A: Fraction of ALN-2232 excreted in urine
Time frame: Predose and up to 8 days postdose (fe)
Part A: Percent Change from Baseline in Body Weight
Time frame: Baseline up to Month 12
Part B and Part C: Concentrations of ALN-2232 in Plasma
Time frame: Predose and up to 6 months postdose
Part B and Part C: Percent Change from Baseline in Body Weight
Time frame: Baseline up to Month 12
Part B and Part C: Change from Baseline in Body Fat Mass and Lean Mass
Measured by dual x-ray absorptiometry (DXA)
Time frame: Baseline up to Month 12
Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.
Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 13 months is below that.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2028 → Apr 2028, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.